Cargando…
Eicosapentaenoic and docosahexaenoic acid supplementation and inflammatory gene expression in the duodenum of obese patients with type 2 diabetes
BACKGROUND: The extent to which long-chain omega-3 polyunsaturated fatty acids (LCn-3PUFA) from fish oil such as eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) exert their anti-inflammatory effects by down-regulating intestinal inflammation in humans is unknown. We investigated the impac...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3718629/ https://www.ncbi.nlm.nih.gov/pubmed/23855973 http://dx.doi.org/10.1186/1475-2891-12-98 |
_version_ | 1782277792821411840 |
---|---|
author | Labonté, Marie-Ève Couture, Patrick Tremblay, André J Hogue, Jean-Charles Lemelin, Valéry Lamarche, Benoît |
author_facet | Labonté, Marie-Ève Couture, Patrick Tremblay, André J Hogue, Jean-Charles Lemelin, Valéry Lamarche, Benoît |
author_sort | Labonté, Marie-Ève |
collection | PubMed |
description | BACKGROUND: The extent to which long-chain omega-3 polyunsaturated fatty acids (LCn-3PUFA) from fish oil such as eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) exert their anti-inflammatory effects by down-regulating intestinal inflammation in humans is unknown. We investigated the impact of LCn-3PUFA supplementation on inflammatory gene expression in the duodenum of obese patients with type 2 diabetes. FINDINGS: This placebo-controlled randomized crossover study included 12 men with type 2 diabetes. After a 4-week run-in period, patients received in a random sequence 5 g/d of fish oil (providing 3 g of EPA + DHA) and a placebo (corn and soybean oil) for 8 weeks each. The two treatment phases were separated by a 12-week washout period. Gene expression was assessed by real-time polymerase chain reaction in duodenal biopsy samples obtained in the fasted state at the end of each treatment phase. Intestinal mRNA expression levels of interleukin (IL)-6 and tumor-necrosis factor (TNF)-α were hardly detectable after either treatment (<100 copies/10(5) copies of the reference gene ATP5o). Intestinal mRNA expression of IL-18 and of the transcription factor signal transducer and activator of transcription 3 (STAT3) was higher (>5000 copies/10(5) copies ATP5o) but still relatively low. EPA + DHA supplementation had no impact on any of these levels (all P ≥ 0.73). CONCLUSIONS: These data suggest that duodenal cells gene expression of pro-inflammatory cytokines is low in patients with type 2 diabetes and not affected by EPA + DHA supplementation. Further studies are warranted to determine if inflammatory gene expression in other tissues surrounding the intestine is modulated by EPA + DHA supplementation. TRIAL REGISTRATION: ClinicalTrials.gov ID: NCT01449773 |
format | Online Article Text |
id | pubmed-3718629 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-37186292013-07-23 Eicosapentaenoic and docosahexaenoic acid supplementation and inflammatory gene expression in the duodenum of obese patients with type 2 diabetes Labonté, Marie-Ève Couture, Patrick Tremblay, André J Hogue, Jean-Charles Lemelin, Valéry Lamarche, Benoît Nutr J Short Report BACKGROUND: The extent to which long-chain omega-3 polyunsaturated fatty acids (LCn-3PUFA) from fish oil such as eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) exert their anti-inflammatory effects by down-regulating intestinal inflammation in humans is unknown. We investigated the impact of LCn-3PUFA supplementation on inflammatory gene expression in the duodenum of obese patients with type 2 diabetes. FINDINGS: This placebo-controlled randomized crossover study included 12 men with type 2 diabetes. After a 4-week run-in period, patients received in a random sequence 5 g/d of fish oil (providing 3 g of EPA + DHA) and a placebo (corn and soybean oil) for 8 weeks each. The two treatment phases were separated by a 12-week washout period. Gene expression was assessed by real-time polymerase chain reaction in duodenal biopsy samples obtained in the fasted state at the end of each treatment phase. Intestinal mRNA expression levels of interleukin (IL)-6 and tumor-necrosis factor (TNF)-α were hardly detectable after either treatment (<100 copies/10(5) copies of the reference gene ATP5o). Intestinal mRNA expression of IL-18 and of the transcription factor signal transducer and activator of transcription 3 (STAT3) was higher (>5000 copies/10(5) copies ATP5o) but still relatively low. EPA + DHA supplementation had no impact on any of these levels (all P ≥ 0.73). CONCLUSIONS: These data suggest that duodenal cells gene expression of pro-inflammatory cytokines is low in patients with type 2 diabetes and not affected by EPA + DHA supplementation. Further studies are warranted to determine if inflammatory gene expression in other tissues surrounding the intestine is modulated by EPA + DHA supplementation. TRIAL REGISTRATION: ClinicalTrials.gov ID: NCT01449773 BioMed Central 2013-07-15 /pmc/articles/PMC3718629/ /pubmed/23855973 http://dx.doi.org/10.1186/1475-2891-12-98 Text en Copyright © 2013 Labonté et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Short Report Labonté, Marie-Ève Couture, Patrick Tremblay, André J Hogue, Jean-Charles Lemelin, Valéry Lamarche, Benoît Eicosapentaenoic and docosahexaenoic acid supplementation and inflammatory gene expression in the duodenum of obese patients with type 2 diabetes |
title | Eicosapentaenoic and docosahexaenoic acid supplementation and inflammatory gene expression in the duodenum of obese patients with type 2 diabetes |
title_full | Eicosapentaenoic and docosahexaenoic acid supplementation and inflammatory gene expression in the duodenum of obese patients with type 2 diabetes |
title_fullStr | Eicosapentaenoic and docosahexaenoic acid supplementation and inflammatory gene expression in the duodenum of obese patients with type 2 diabetes |
title_full_unstemmed | Eicosapentaenoic and docosahexaenoic acid supplementation and inflammatory gene expression in the duodenum of obese patients with type 2 diabetes |
title_short | Eicosapentaenoic and docosahexaenoic acid supplementation and inflammatory gene expression in the duodenum of obese patients with type 2 diabetes |
title_sort | eicosapentaenoic and docosahexaenoic acid supplementation and inflammatory gene expression in the duodenum of obese patients with type 2 diabetes |
topic | Short Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3718629/ https://www.ncbi.nlm.nih.gov/pubmed/23855973 http://dx.doi.org/10.1186/1475-2891-12-98 |
work_keys_str_mv | AT labontemarieeve eicosapentaenoicanddocosahexaenoicacidsupplementationandinflammatorygeneexpressionintheduodenumofobesepatientswithtype2diabetes AT couturepatrick eicosapentaenoicanddocosahexaenoicacidsupplementationandinflammatorygeneexpressionintheduodenumofobesepatientswithtype2diabetes AT tremblayandrej eicosapentaenoicanddocosahexaenoicacidsupplementationandinflammatorygeneexpressionintheduodenumofobesepatientswithtype2diabetes AT hoguejeancharles eicosapentaenoicanddocosahexaenoicacidsupplementationandinflammatorygeneexpressionintheduodenumofobesepatientswithtype2diabetes AT lemelinvalery eicosapentaenoicanddocosahexaenoicacidsupplementationandinflammatorygeneexpressionintheduodenumofobesepatientswithtype2diabetes AT lamarchebenoit eicosapentaenoicanddocosahexaenoicacidsupplementationandinflammatorygeneexpressionintheduodenumofobesepatientswithtype2diabetes |